KPC(SH:600422)2021-10-21 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥1,934,636,541.69, a decrease of 3.26% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2021 was ¥101,793,706.35, down 19.46% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥55,090,634.38, a significant decrease of 46.81% compared to the same period last year[6]. - The basic earnings per share for Q3 2021 was ¥0.1342, reflecting a decline of 19.88% year-on-year[8]. - Total revenue for the first three quarters of 2021 reached ¥6,027,708,151.79, an increase of 11.2% compared to ¥5,424,015,660.46 in the same period of 2020[28]. - Net profit for the first three quarters of 2021 was ¥524,886,917.47, an increase of 23.4% from ¥425,234,819.34 in the previous year[31]. - The total comprehensive income attributable to the parent company's owners was CNY 432,871,509.32, compared to CNY 352,372,292.50 in the previous year, reflecting an increase of approximately 22.8%[37]. - The net profit for the period was CNY 437,400,517.23, up from CNY 352,274,216.15, indicating a growth of about 24.2% year-over-year[35]. - Basic and diluted earnings per share were both CNY 0.5722, compared to CNY 0.4627 in the same period last year, representing a rise of approximately 23.7%[37]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,337,323,152.61, an increase of 2.65% compared to the end of the previous year[8]. - Non-current assets totaled ¥2,707,271,922.46, up from ¥2,558,446,530.15, representing a growth of 5.8%[28]. - Total assets increased to ¥8,337,323,152.61 from ¥8,122,108,294.77, reflecting a rise of 2.6%[28]. - Total liabilities decreased to ¥3,469,246,719.46 from ¥3,519,443,681.62, a reduction of 1.4%[28]. - Shareholders' equity increased to ¥4,868,076,433.15 from ¥4,602,664,613.15, showing a growth of 5.8%[28]. - The company reported a decrease in accounts payable to ¥724,959,383.15 from ¥651,389,848.17, indicating a reduction of 11.3%[28]. - Current liabilities totaled 3,126,720,602.76, slightly increasing to 3,133,150,449.41, with a change of 6,429,846.65[49]. - Total liabilities increased from 3,519,443,681.62 to 3,560,512,257.67, reflecting a rise of 41,068,576.05[49]. Cash Flow - The net cash flow from operating activities for the year-to-date was negative at -¥159,247,452.70, a decline of 201.14% compared to the previous year[6]. - Cash inflow from operating activities totaled CNY 6,430,676,381.46, slightly down from CNY 6,511,529,799.95, a decrease of about 1.2%[39]. - The net cash flow from operating activities was negative at CNY -159,247,452.70, contrasting with a positive CNY 157,449,529.41 in the previous year[41]. - Cash flow from investing activities showed a net outflow of CNY -275,331,474.60, compared to a larger outflow of CNY -554,625,344.07 in the prior year[41]. - The company reported cash and cash equivalents at the end of the period amounting to CNY 846,439,630.42, down from CNY 891,950,709.30 at the end of the previous year[41]. - Total cash inflow from financing activities was CNY 905,848,024.71, a decrease from CNY 964,690,410.00 in the same period last year[41]. Research and Development - The company invested CNY 108.79 million in R&D, representing a 21.03% increase compared to the same period last year[16]. - Research and development expenses for the first three quarters of 2021 amounted to ¥72,264,559.68, compared to ¥61,074,605.09 in 2020, marking an increase of 18.0%[31]. - The company continues to focus on differentiated R&D in key therapeutic areas such as cardiovascular, orthopedic, and rheumatology[16]. Product Development and Sales - The company reported a significant increase in sales for key products, with "Kun Pharmaceutical Xuesaitong" capsules growing by 16.94% and "Shenling Baizhu" granules by 67.28% year-on-year[13]. - The health segment achieved revenue of CNY 44.10 million, a year-on-year increase of 137.83% as of September[16]. - Retail sales of Kun Pharmaceutical's Xuesaitong soft capsules grew by 94.51% year-on-year, contributing to the overall revenue of CNY 930 million, which is a 30.06% increase year-on-year[16]. - Clinical trials for the innovative drug KYAZ01-2011-020 for ischemic stroke are progressing smoothly, with single-dose tolerance tests completed[16]. - The company received production approval for pain relief drug Parecoxib sodium and antihypertensive drug Valsartan Amlodipine tablets, enhancing its product pipeline in cardiovascular and orthopedic fields[16]. Shareholder Information - The total number of ordinary shareholders reached 50,051, with the top ten shareholders holding 48.38% of the shares[17]. - Huali Pharmaceutical Group Co., Ltd. is the largest shareholder, holding 30.98% of the shares[17]. Tax and Expenses - The company experienced a decrease in tax expenses, with CNY 87,486,400.24 reported compared to CNY 72,960,603.19 previously, reflecting an increase of approximately 19.9%[35].